undefined undefined
NaN.000
NaN.00%
Merck (NYSE:MRK) has discontinued the vibostolimab and pembrolizumab coformulation arm of a late-stage skin cancer trial. KeyVibe-010, a randomized Phase 3 trial, was testing the investigational cofor...
05-13 19:58
HC Wainwright & Co.:重申Agenus(AGEN.US)评级,由买入调整至买入评级, 目标价40.00美元。
05-08 02:11
HC Wainwright & Co. analyst Emily Bodnar reiterates Agenus (NASDAQ:AGEN) with a Buy and maintains $40 price target.
05-08 02:07
Unity Software(U.US) reported fourth-quarter financial results after the market...
05-08 02:06
H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Agenus (AGEN – ...
05-08 00:45
Gainers: Clearmind Medicine (CMND) +34%. Bioventus (BVS) +21%. FibroGen (FGEN) +19%. NanoViricides (NNVC) +19%. Artivion (AORT) +17%. Losers: Holdco Nuvo Group D.G (NUVO) -27%. Enanta Pharmaceuticals ...
05-07 22:01
Ligand Pharmaceuticals (NASDAQ:LGND) and Agenus (AGEN) said they have entered into a royalty financing agreement to support AGEN's key development initiatives in the ongoing BOT/BAL clinical developme...
05-07 20:02
Agenus press release (NASDAQ:AGEN): Q1 GAAP EPS of -$3.04 beats by $0.18. Revenue of $28M (+22.3% Y/Y) misses by $19.17M. The company ended our first quarter 2024 with a cash and cash equivalent balan...
05-07 19:46
Agenus (NASDAQ:AGEN) reported quarterly losses of $(3.04) per share which beat the analyst consensus estimate of $(3.14) by 3.18 percent. The company reported quarterly sales of $28.005 million which missed the analyst
05-07 19:40
Capital infusion will support botensilimab and balstilimab (BOT/BAL) clinical development, confirmatory Phase 3 trial, and launch readiness activitiesLigand entitled to royalties and milestone payments on six
05-07 19:31